Get the Stockscreener App
4.31
33.85%
1.09
After Hours:
4.31
Nrx Pharmaceuticals Inc stock is traded at $4.31, with a volume of 4.32M.
It is up +33.85% in the last 24 hours and up +46.60% over the past month.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
See More
Previous Close:
$3.22
Open:
$3.29
24h Volume:
4.32M
Relative Volume:
4.27
Market Cap:
$156.15M
Revenue:
$1.23M
Net Income/Loss:
$-28.62M
P/E Ratio:
-2.7456
EPS:
-1.5698
Net Cash Flow:
$-14.11M
1W Performance:
+42.24%
1M Performance:
+46.60%
6M Performance:
+84.19%
1Y Performance:
+64.50%
1-Day Range:
$3.26
$4.445
1-Week Range:
$2.86
$4.445
52-Week Range:
$1.62
$4.445
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Name
Nrx Pharmaceuticals Inc
Sector
Industry
Phone
484-254-6134
Address
1201 ORANGE STREET, WILMINGTON
Compare NRXP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
4.31 | 116.66M | 1.23M | -28.62M | -14.11M | -1.5698 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | H.C. Wainwright | Buy |
| Apr-02-25 | Initiated | BTIG Research | Buy |
Nrx Pharmaceuticals Inc Stock (NRXP) Latest News
Here is why NRx Pharmaceuticals, Inc. (NRXP) is among the Best Rated Penny Stocks to Buy According to Wall Street Analysts - Insider Monkey
NRX Pharmaceuticals Inc (NRXP) Stock Price, Quote, News & History - Benzinga
Nasdaq withdraws NRXP Warrant listing (NRXP) — Form 25 notice - Stock Titan
NRXP Stock Price, Quote & Chart | NRX PHARMACEUTICALS INC (NASDAQ:NRXP) - ChartMill
My Top 3 Biotech Stocks for May 2026 - The Motley Fool
NRx Pharmaceuticals: 'Sell' On ZYESAMI/NRX-101 Failures & Depression Market Uncertainty (NASDAQ:NRXP) - Seeking Alpha
NRx Pharmaceuticals, Inc. (NRXP) reports Q1 loss, lags revenue estimates - MSN
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update - Sahm
NRx Pharmaceuticals beats EPS estimates but misses revenue, awaits FDA decisions on key drugs. - Pluang
symbol__ Stock Quote Price and Forecast - CNN
NRx Pharmaceuticals targets summer 2026 KETAFREE approval as it scales to 1M units per batch - MSN
NRXP: Regulatory advances, clinic growth, and a 74% net loss reduction marked a transformative Q1 2026 - TradingView
NRXP: Regulatory advances, clinic growth, and a 74% net loss reduction marked a strong Q1 2026 - TradingView
NRx Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
Earnings call transcript: NRX Pharmaceuticals sees 74% reduction in net loss in Q1 2026 - Investing.com
NRXP: Advanced CNS drug pipeline, reduced net loss, and expanded clinical footprint in Q1 2026 - TradingView
FDA ketamine decision expected in Q3 2026 as NRx starts million-dose production - Stock Titan
Press Release: NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
NRX Pharmaceuticals, Inc.Warrant (NQ: NRXPW - The Chronicle-Journal
NRXP Financials: Income Statement, Balance Sheet & Cash Flow | Nrx Pharmaceuticals Inc - Stock Titan
NRX Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
NRx Pharmaceuticals, Inc. (NRXP) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
NRX Pharmaceuticals, Inc. 1Q 2026: Revenue $1.07M, Net income ($1.43M), EPS ($0.04) — 10-Q Summary - TradingView
NRx Pharmaceuticals (NRXP) Q1 2026 loss narrows but going concern warning remains - Stock Titan
Anson Funds discloses 1.74M shares in NRX Pharmaceuticals (NRXP) - Stock Titan
NRx Pharmaceuticals earnings are imminent; these most accurate analysts revise forecasts ahead of earnings call - MSN
NRX Pharmaceuticals Inc expected to post earnings of 29 cents a shareEarnings Preview - TradingView
NRx Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga
NRx Pharmaceuticals, Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update - Investing News Network
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update - The Manila Times
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First - GlobeNewswire
NRXP: NRx PharmaceuticalsInteractive Chart - Zacks Investment Research
NRx Pharmaceuticals receives FDA clearance for depression trial - Investing.com UK
NRx Pharmaceuticals Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and Suicidality - Investing News Network
NRx Pharmaceuticals receives FDA clearance for depression trial By Investing.com - Investing.com Australia
NRx Pharmaceuticals Receives FDA Clearance for NRX-101 and rTMS Clinical Trial Targeting Depression and Suicidality - geneonline.com
NRx Pharmaceuticals (NasdaqNrxp) announces FDA clearance to proceed with clinical trial of NRx-101 in combination with robotic-enabled transcranial magnetic stimulation in patients with depression and suicidality - marketscreener.com
NRx Pharmaceuticals (NasdaqNrxp) Announces FDA Clearance To Proceed With Clinical Trial Of Nrx-101 In Combination With Robotic-Enabled Transcranial Magnetic Stimulation In Patients With Depression And Suicidality - TradingView
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and Suicidality - marketscreener.com
FDA clears NRx study pairing TMS and NRX-101 for depression, suicidality - Stock Titan
NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital - Moomoo
NRX Pharmaceuticals Price Target Maintained With a $34.00/Share by D. Boral Capital - Moomoo
NRx Pharmaceuticals (NASDAQ: NRXP) Initiates First Commercial Manufacturing Order For Preservative-Free Ketamine - Barchart
NRx Pharmaceuticals Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine - Investing News Network
NRx Pharmaceuticals (N A S D A Q: NRXP) Accelerates Into National Spotlight as Manufacturing Launch, Federal Policy & AI-Driven Breakthroughs Converge - PRLog
NRx Pharmaceuticals, Inc. (NRXP) Latest Stock News & Headlines - Yahoo Finance
Amid ketamine shortages, NRx begins making a preservative-free U.S. version - Stock Titan
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine - marketscreener.com
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Sees Large Growth in Short Interest - MarketBeat
NRx Pharmaceuticals, Inc. (NRXP) surpasses Q4 earnings estimates - MSN
NRx Reports FDA Feedback, Progress on Ketamine Application - MyChesCo
Nrx Pharmaceuticals Inc Stock (NRXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):